Design Therapeutics Inc logo

Design Therapeutics Inc(DSGN)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$10.47
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for DSGN

11/13/2026: DSGN (1-star) is currently NOT-A-BUY. Pass it for now.

Design Therapeutics Inc is a clinical-stage biopharmaceutical stock focused on creating novel GeneTAC small molecule therapies for serious genetic disorders. Its main business strength lies in its innovative platform designed to address hard-to-treat repeat expansion diseases like Friedreich ataxia. The primary investment story centers on the potential clinical validation of its lead pipeline candidates, which could unlock substantial long-term growth. However, the company faces high risks typical of early-stage biotech, including clinical trial uncertainties, lack of commercial revenue, and potential financing dilution. This stock is best suited for risk-tolerant growth investors willing to monitor clinical data readouts and regulatory updates closely.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitOffers long-term capital appreciation potential tied to clinical pipeline success, but carries high binary clinical risk.
Momentum investorStrong fit while signal remains positiveStock price can experience sharp rallies or declines around clinical trial data readouts and regulatory updates.
Value investorWeak fitLacks traditional valuation metrics like earnings, revenue streams, or price-to-earnings ratios due to its pre-revenue status.
Dividend investorWeak fitThe company does not pay dividends and retains all capital to fund clinical research.
Low-risk investorWeak fitHigh volatility and inherent clinical trial failure risks make it unsuitable for risk-averse investors.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighStock prices react sharply to clinical trial results, regulatory news, and biotech sector sentiment.
Valuation riskMedium / highValuations are heavily dependent on future projections and scientific assumptions rather than current cash flows.
Competition risk (genetic medicine competition)HighAlternative therapeutic modalities like gene editing and RNA-targeted drugs threaten market potential.
Business qualityMediumFeatures a specialized scientific platform, though unproven by commercial product launches.
Dividend incomeLow / noneNo dividend is paid or anticipated in the near term.
Execution riskHighSuccess relies entirely on navigating complex clinical trials and regulatory approvals successfully.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 670.46M USD
Price to earnings Ratio -
1Y Target Price 21.57
Price to earnings Ratio -
1Y Target Price 21.57
Volume (30-day avg) 446.4K shares
Beta 1.75
52 Weeks Range 7.24 - 17.25
Updated Date 11/15/2026
52 Weeks Range 7.24 - 17.25
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -1.2

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Highly Choppy
PRICE STABILITY

Highly Choppy

The stock has experienced frequent, large price swings that make its near-term movement less predictable.

Analysis of Past Performance

Type Stock
Historic Profit -20.43%
Avg. Invested days 31
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
DSGN receives a 2-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
DSGN has moderate overall fundamentals (3 stars), with moderate financial health, soft growth momentum, and strong ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-40.7%), soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
DSGN's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
DSGN's growth profile is soft, with the least-weak measure being revenue growth at +0.0% FY2025 versus FY2024. By comparison, while earnings growth (-40.7%, negative) and free-cash-flow growth (-25.6%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 80.1% and approximately 58.8% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 31.24% supports management-shareholder alignment.

Top 5 Institutional Investors

SR ONE CAPITAL MANAGEMENT, LP 10.19%
Logos Global Management LP 4.68%
Baker Bros Advisors LP 4.18%
Driehaus Capital Management LLC 4.16%
BlackRock Inc 4.15%

Unit Economics (Per $1K Revenue)

★★★★★
DSGN generates approximately $-0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
DSGN has a liquid profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Therapeutic Development & LicensingFuture potential commercial sales of gene-targeting drugs and milestone or royalty payments from potential collaborative partnerships.The company does not currently sell commercial products and operates at a loss while developing its drug pipeline.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 464.05M
Price to Sales(TTM) 29402.82
Enterprise Value 464.05M
Price to Sales(TTM) 29402.82
Enterprise Value to Revenue 17818.79
Enterprise Value to EBITDA -0.84
Shares Outstanding 64.04M
Shares Floating 37.65M
Shares Outstanding 64.04M
Shares Floating 37.65M
Percent Insiders 31.24
Percent Institutions 80.15

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.